The present work was designed to increase understanding of the nature and degree to which a novel δ/γ PPAR agonist might be beneficial for treating or reducing severity of neurodegeneration in structural targets of brain insulin resistance in AD. The gene discussed is PPARA; the disease is Alzheimer disease.